Literature DB >> 33481839

Renal function in a cohort of HIV-infected patients initiating antiretroviral therapy in an outpatient setting in Ethiopia.

Temesgen Fiseha1, Angesom Gebreweld2.   

Abstract

AIM: To evaluate the prevalence and associated factors of abnormal renal function among Ethiopian HIV-infected patients at baseline prior to initiation of antiretroviral therapy (ART) and during follow-up.
METHODS: We conducted a retrospective observational cohort study of HIV infected patients who initiated ART at the outpatient ART clinic of Mehal Meda Hospital of North Shewa, Ethiopia from January 2012 to August 2018. Demographic and clinical data were abstracted from the medical records of patients. Renal function was assessed by estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation. Univariate and multivariate analysis were conducted to determine the factors associated with abnormal renal function at baseline and during follow-up.
RESULTS: Among 353 patients, 70 (19.8%) had baseline eGFR <60 ml/min/1.73m2 and 102 (28.9%) had eGFR = 60-89.9 ml/min/1.73m2. Factors associated with baseline renal impairment (eGFR <60 ml/min/1.73m2) included female sex (AOR = 3.52, CI 1.75-7.09), CD4 count < 200 cells/mm3 (AOR = 2.75, CI 1.40-5.42), BMI < 25 Kg/m2 (AOR = 3.04, CI 1.15-8.92), low hemoglobin (AOR = 2.19, CI 1.16-4.09) and high total cholesterol (AOR = 3.15, CI 1.68-5.92). After a median of 3.0 years of ART, the mean eGFR declined from 112.9 ± 81.2 ml/min/1.73m2 at baseline to 93.9 ± 60.6 ml/min/1.73m2 (P < 0.001). The prevalence of renal impairment increased from 19.8% at baseline to 22.1% during follow-up. Of 181 patients with baseline normal renal function, 49.7% experienced some degree of renal impairment. Older age (AOR = 3.85, 95% CI 2.03-7.31), female sex (AOR = 4.18, 95% CI 2.08-8.40), low baseline CD4 (AOR = 2.41, 95% CI 1.24-4.69), low current CD4 count (AOR = 2.32, 95% CI 1.15-4.68), high BMI (AOR = 2.91, 95% CI 1.49-5.71), and low hemoglobin (AOR = 3.38, 95% CI 2.00-7.46) were the factors associated with renal impairment during follow-up.
CONCLUSION: Impaired renal function was common in HIV-infected patients initiating ART in an outpatient setting in Ethiopia, and there appears to be a high prevalence of renal impairment after a median ART follow-up of 3 years. There is a need for assessment of renal function at baseline before ART initiation and regular monitoring of renal function for patients with HIV during follow-up.

Entities:  

Year:  2021        PMID: 33481839      PMCID: PMC7822244          DOI: 10.1371/journal.pone.0245500

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  49 in total

1.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

2.  Deteriorating renal function and clinical outcomes in HIV-positive persons.

Authors:  Amanda Mocroft; Lene Ryom; Josip Begovac; Antonella D'Arminio Monforte; Anne Vassilenko; Jose Gatell; Eric Florence; Vidar Ormaasen; Ole Kirk; Jens D Lundgren
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

3.  Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.

Authors:  Katherine W Kooij; Liffert Vogt; Ferdinand W N M Wit; Marc van der Valk; Rosan A van Zoest; Abraham Goorhuis; Maria Prins; Frank A Post; Peter Reiss
Journal:  J Infect Dis       Date:  2017-09-15       Impact factor: 5.226

4.  Antiretroviral therapy in the treatment of HIV-associated nephropathy.

Authors:  Mohamed G Atta; Joel E Gallant; M Hafizur Rahman; Nagapradeep Nagajothi; Lorraine C Racusen; Paul J Scheel; Derek M Fine
Journal:  Nephrol Dial Transplant       Date:  2006-07-24       Impact factor: 5.992

5.  Prevalence and Pattern of Chronic Kidney Disease in Antiretroviral-Naïve Patients with HIV/AIDS.

Authors:  Tewogbade Adeoye Adedeji; Nife O Adedeji; Simeon A Adebisi; Ademola A Idowu; Michael B Fawale; Kayode A Jimoh
Journal:  J Int Assoc Provid AIDS Care       Date:  2015-05-26

6.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Authors:  Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

7.  Chronic renal failure among HIV-1-infected patients.

Authors:  Amanda Mocroft; Ole Kirk; Jose Gatell; Peter Reiss; Panagiotis Gargalianos; Kai Zilmer; Marek Beniowski; Jean-Paul Viard; Schlomo Staszewski; Jens D Lundgren
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

8.  Renal dysfunction among adult HIV/AIDS patients on antiretroviral therapy at a tertiary facility in Ghana.

Authors:  Dorcas Obiri-Yeboah; Yaw Asante Awuku; Wonderful Alofa; Alice Charwudzi; Ebenezer Aniakwa-Bonsu; Evans Obboh; Paul Nsiah
Journal:  BMC Nephrol       Date:  2018-11-21       Impact factor: 2.388

9.  The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.

Authors:  Tino Salome; Ivan Kasamba; Billy Nsubuga Mayanja; Patrick Kazooba; Jackson Were; Pontiano Kaleebu; Paula Munderi
Journal:  AIDS Res Ther       Date:  2016-08-30       Impact factor: 2.250

10.  The metabolic syndrome and renal function in an African cohort infected with human immunodeficiency virus.

Authors:  Edith Phalane; Carla M T Fourie; Aletta E Schutte
Journal:  South Afr J HIV Med       Date:  2018-09-20       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.